Acute lymphocytic leukemia Market
Dec 14, 2023
Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts
Date of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
